title: [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].
abstract: We report three cases of patients with Parkinson's disease without dementia, admitted to our hospital because of hallucinations. The anti-Parkinson medication was adapted and the patients started with rivastigmine. As a result, hallucinations no longer occurred. A 79 years old man also required short-term quetiapine because of agitation and anti-Parkinson doses were without side effects, as a result of which mobility improved. An 84 years old woman reported mild side effects of rivastigmine, without consequences, whereas her mobility appeared to be good. A 72 years old woman reported mild memory problems upon admission, which improved during admission, as did her mobility after increasing the anti-Parkinson medication doses. Treatment of rivastigmine can be useful in the therapeutic dilemma in the treatment of hallucinations in patients with Parkinson's disease (start anti-psychotic or reduce anti-Parkinson medication). In addition to adapting anti-Parkinson doses and sometimes short-term treating with an anti-psychotic, treatment with rivastigmine appears to be a quick improvement, without serious side effects. Also, mobility can improve, due to the possibility of increasing the anti-Parkinson doses, if necessary. Because of the many remaining questions, prospective randomised trials are needed.
authors.affiliation: Jeroen Bosch Ziekenhuis, 's-Hertogenbosch.
authors.forename: J M P
authors.initials: JM
authors.lastname: Rovers
authors.forename: P L J
authors.initials: PL
authors.lastname: Dautzenberg
authors.forename: J P
authors.initials: JP
authors.lastname: ter Bruggen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006212:Hallucinations / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications*; D048448:Phenylcarbamates / Q000009:adverse effects / Q000627:therapeutic use*; D000068836:Rivastigmine; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine